Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04212013 · ClinicalTrials.gov registry record · Phase 3
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
A Phase 3 study of Marginal Zone Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
- 10
- Study locations
NCT04212013: Active Phase 3 study of Marginal Zone Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04212013 is a Phase 3 study of Marginal Zone Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04212013, a Phase 3 study of Marginal Zone Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.
Primary Outcome
per the RECIL criteria
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rituximab
- DRUG Ibrutinib
Study Locations (10)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
District of Columbia
- George Washington Cancer Center - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Minnesota
- Mayo Clinic Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 3 |
What the registry record for NCT04212013 still lists
NCT04212013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04212013 lists 10 locations in 5 states (New York, New Jersey, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT04212013 about?
NCT04212013 is a clinical study titled "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma". The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which...
What is the current status of trial NCT04212013?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2019-12-23. Estimated completion is 2027-03-18.
What conditions does trial NCT04212013 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma.
What interventions are being tested in trial NCT04212013?
The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT04212013?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04212013 being conducted?
This trial has 10 study locations across District of Columbia, Florida, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04212013's enrollment target sits among peer trials
23 43rd of 49 higher than 6 of 49 other Marginal Zone Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Marginal Zone Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
RECRUITING · Phase 3
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI